Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.
DrugDrug NameDrug Indication
DB11300ThrombinNot Available
DB11311ProthrombinFor use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. Prothrombin is administered as part of a cocktail containing several coagulation factors.
DB11312Protein CNot Available
DB11330Factor IX Complex (Human)Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy.
DB11569Ixekizumab Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DB11595AtezolizumabFor the treatment of patients with locally advanced or metastatic urothelial carcinoma who: 1) have disease progression during or following platinum-containing chemotherapy, and 2) have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
DB11598Antithrombin III humanAntithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
DB11621Human Varicella-Zoster Immune GlobulinIndicated for preventing and reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals within 4 days of exposure to varicella zoster virus.
DB11646ConatumumabNot Available
DB11657TabalumabNot Available
DB11668Rusalatide acetateNot Available
DB11680FiclatuzumabNot Available
DB11685FigitumumabNot Available
DB11714DurvalumabDurvalumab is indicated for patients with urothelial carcinoma, such as urinary bladder, urethra or ureter cancer. Patients with prolonged disease progression due to failed platinum-based chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment. Its clinical effectiveness is especially enhanced in PD-L1-positive patient groups [A19123].
DB11715BapineuzumabNot Available
DB11746OnartuzumabNot Available
DB11756SolanezumabNot Available
DB11767SarilumabNot Available
DB11771TremelimumabNot Available
DB11776BrodalumabBrodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
DB11803SirukumabNot Available
DB11826LampalizumabNot Available
DB11834GuselkumabIndicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DB11840DalotuzumabNot Available
DB11849EmibetuzumabNot Available
DB11856LigelizumabNot Available
DB11857SeribantumabNot Available
DB11862LandogrozumabNot Available
DB11866RomosozumabNot Available
DB11945AvelumabIndicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
DB11959CrenezumabNot Available
DB11972RilotumumabNot Available
DB11976AnifrolumabNot Available
DB11988OcrelizumabOcrelizumab is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.
DB12023BenralizumabNot Available
DB12034GantenerumabNot Available
DB12053VisilizumabNot Available
DB12089Lorvotuzumab mertansineNot Available
DB12090PatritumabNot Available
DB12102FulranumabNot Available
DB12104TarextumabNot Available
DB12119GevokizumabNot Available
DB12142DuligotuzumabNot Available
DB12159DupilumabDupilumab is a monoclonal antibody designed for the treatment of atopic diseases such as eczema.
DB12169TralokinumabNot Available
DB12189EtrolizumabNot Available
DB12205GanitumabNot Available
DB12213EtaracizumabNot Available
DB12240Polatuzumab VedotinNot Available
DB12246InclacumabNot Available
DB12250CixutumumabNot Available
DB12261AscrinvacumabNot Available
DB12274AducanumabNot Available
DB12335TanezumabNot Available
DB12363DusigitumabNot Available
DB12396FresolimumabNot Available
DB12409Vatreptacog alfaNot Available
DB12456BococizumabNot Available
DB12489Mirvetuximab SoravtansineNot Available
DB12498MogamulizumabNot Available
DB12530InebilizumabNot Available
DB12534MavrilimumabNot Available
DB12560BlosozumabNot Available
DB12584BimagrumabNot Available
DB12589DacetuzumabNot Available
DB12609TovetumabNot Available
DB12698IbalizumabNot Available
DB12699BalugrastimNot Available
DB12701IntetumumabNot Available
DB12718CarlumabNot Available
DB12726MonteplaseNot Available
DB12732FirategrastNot Available
DB12734DemcizumabNot Available
DB12775AbituzumabNot Available
DB12807Naptumomab EstafenatoxNot Available
DB12815CrotedumabNot Available
DB12820ConcizumabNot Available
DB12826DepatuxizumabNot Available
DB12844RontalizumabNot Available
DB12845AmatuximabNot Available
DB12849ClazakizumabNot Available
DB12891OzanezumabNot Available
DB12893Sacituzumab govitecanNot Available
DB12909Factor XIII (human)Not Available
DB12943MilatuzumabNot Available
DB12976RobatumumabNot Available
DB13045RacotumomabNot Available
DB13127OlokizumabNot Available
DB13133Von Willebrand Factor HumanNot Available
DB13148Coagulation factor X humanCoagulation Factor X (Human), is a plasma-derived human blood coagulation factor is indicated for subjects with hereditary Factor X deficiency for: •On-demand treatment and control of bleeding episodes •Perioperative management of bleeding in patients with mild hereditary Factor X deficiency
DB13149Protein S humanFor use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors.
DB13150Coagulation factor VII humanMay be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures.
DB13192Antihemophilic factor humanNot Available
DB00002CetuximabCetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
DB00005EtanerceptEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.
DB00009AlteplaseFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
DB00013UrokinaseUrokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
DB00015ReteplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00025Antihemophilic factor, human recombinantFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
DB00028Immune Globulin HumanIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.
DB00029AnistreplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00031TenecteplaseFor treatment of myocardial infarction and lysis of intracoronary emboli
DB00036Coagulation factor VIIa Recombinant HumanFor treatment of hemorrhagic complications in hemophilia A and B
DB00043OmalizumabFor treatment of asthma caused by allergies
DB00051AdalimumabFor treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
DB00054AbciximabAbciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
DB00055Drotrecogin alfaFor reduction of mortality in patients with severe sepsis.
DB00056Gemtuzumab ozogamicinIndicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
DB00057Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
DB00058Alpha-1-proteinase inhibitorFor chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
DB00062Human Serum AlbuminFor treatment of severe blood loss, hypervolemia, and hypoproteinemia.
DB00065InfliximabTo manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.
DB00072TrastuzumabFor treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
DB00073RituximabFor treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
DB00074BasiliximabFor prophylactic treatment of kidney transplant rejection
DB00075MuromonabFor treatment of organ transplant recipients, prevention of organ rejection
DB00078Ibritumomab tiuxetanFor treatment of non-Hodgkin's lymphoma
DB00081TositumomabFor treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
DB00086StreptokinaseFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DB00087AlemtuzumabAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
DB00089Capromab pendetideFor diagnosis of prostate cancer and detection of intra-pelvic metastases.
DB00095EfalizumabFor the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
DB00098Antithymocyte immunoglobulin (rabbit)For prevention of renal transplant rejection
DB00102BecaplerminFor topical treatment of skin ulcers (from diabetes)
DB00108NatalizumabFor treatment of multiple sclerosis.
DB00110PalivizumabFor prophylaxis of respiratory diseases casued by respiratory syncytial virus.
DB00111DaclizumabZenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
DB00112BevacizumabAs part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
DB00113Technetium Tc-99m arcitumomabFor imaging colorectal tumors
DB01257EculizumabFor the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
DB01269PanitumumabFor the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB01270RanibizumabFor the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB01277MecaserminFor the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
DB01281AbataceptFor the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
DB01373CalciumCalcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades.
DB02261Platelet Activating FactorNot Available
DB04901GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB04949PexelizumabFor the treatment of inflammation during cardiac surgery.
DB04956AfelimomabInvestigated for use/treatment in sepsis and septicemia.
DB04958EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DB04962BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB04964OregovomabInvestigated for use/treatment in ovarian cancer.
DB04988IGN311Intended for the treatment of various forms of cancer.
DB05006AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
DB05097LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
DB05101MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
DB05111FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
DB05136BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
DB05139CR002Investigated for use/treatment in nephropathy.
DB05209SYM001Investigated for use/treatment in thrombocytopenia.
DB05276Hepatitis B Immune GlobulinInvestigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
DB05299keyhole limpet hemocyaninInvestigated for use/treatment in bladder cancer and solid tumors.
DB05336ObiltoxaximabInvestigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
DB05405XTL-001Investigated for use/treatment in hepatitis (viral, B).
DB05437RIGScan CR49Investigated for use/treatment in colorectal cancer and solid tumors.
DB05459BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
DB05496OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
DB05578RamucirumabFor use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
DB05595FarletuzumabInvestigated for use/treatment in ovarian cancer.
DB05679UstekinumabUstekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB05793PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DB05797TNX-901Investigated for use/treatment in allergic reaction.
DB05889Inotuzumab ozogamicinIndicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).
DB05892RI 624Investigated for use/treatment in pain (acute or chronic).
DB05915MYO-029Investigated for use/treatment in muscular dystrophy.
DB06043OlaratumabOlaratumab is indicated, in combination with doxorubicin, for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
DB06101IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
DB06168CanakinumabUsed in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
DB06186IpilimumabIpilimumab is indicated for the treatment of unresectable or metastatic melanoma in adults. It is also used to reduce the risk of the deadly skin cancer returning after surgery.
DB06273TocilizumabIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DB06317ElotuzumabIndicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
DB06366PertuzumabPertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DB06404Human C1-esterase inhibitorFor routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).
DB06602reslizumabInvestigated for use/treatment in esophageal disorders and pediatric indications.
DB06612MepolizumabMepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history
DB06643DenosumabProlia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
DB06650OfatumumabOfatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
DB06674GolimumabUsed in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
DB06681BelataceptFor prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
DB08870Brentuximab vedotinUsed in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
DB08879BelimumabAdjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
DB08902RaxibacumabRaxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
DB08904Certolizumab pegolReducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
DB08935ObinutuzumabObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
DB09029SecukinumabFor the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy.
DB09033VedolizumabVedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
DB09035NivolumabNivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.
DB09036SiltuximabSiltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
DB09037PembrolizumabPembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:  patients with unresectable or metastatic melanoma.  patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.  patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.  patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
DB09045DulaglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09052BlinatumomabIndicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09077DinutuximabDinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.
DB09105Asfotase AlfaIndicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).
DB09109Turoctocog alfaNot Available
DB09222Fibrinogen HumanFor the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
DB09264IdarucizumabFor use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.
DB09302AlirocumabAlirocumab is indicated as an adjunct to diet and maximally tolerated statin therapy in adults who require additional LDL-cholesterol (LDL-C) lowering due to heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
DB09303EvolocumabFor the treatment of heterozygous/homozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional LDL-cholesterol lowering.
DB09312Antilymphocyte immunoglobulin (horse)For prevention of renal transplant rejection and for the treatment of aplastic anemia.
DB09331DaratumumabFor the treatment of patients with multiple myeloma who have received at least three prior lines of therapy (a proteasome inhibitor (PI) and an immunomodulatory agent) or who are double-refractory to a PI and an immunomodulatory agent. This indication was approved by accelerated approval based on response rate.
DB09559NecitumumabNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
DrugDrug NameTargetType
DB11300ThrombinProteinase-activated receptor 1target
DB11300ThrombinProteinase-activated receptor 4target
DB11311ProthrombinFibrinogen alpha chaintarget
DB11311ProthrombinFibrinogen beta chaintarget
DB11311ProthrombinCoagulation factor XIII A chaintarget
DB11311ProthrombinCarboxypeptidase B2target
DB11311ProthrombinCoagulation factor Xenzyme
DB11569IxekizumabInterleukin-17Atarget
DB11595AtezolizumabProgrammed cell death 1 ligand 1target
DB11598Antithrombin III humanAntithrombin-IIItarget
DB11714DurvalumabProgrammed cell death 1 ligand 1target
DB11714DurvalumabT-lymphocyte activation antigen CD80target
DB11834GuselkumabInterleukin-23 subunit alphatarget
DB11945AvelumabProgrammed cell death 1 ligand 1target
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB12119GevokizumabInterleukin-1 betatarget
DB12159DupilumabInterleukin-4 receptor subunit alphatarget
DB12250CixutumumabInsulin-like growth factor 1 receptortarget
DB12698IbalizumabFree fatty acid receptor 4target
DB13149Protein S humanCoagulation factor Vtarget
DB13149Protein S humanCoagulation factor Xtarget
DB13149Protein S humanVitamin K-dependent protein Ctarget
DB13150Coagulation factor VII humanTissue factortarget
DB13150Coagulation factor VII humanCoagulation factor Xtarget
DB13150Coagulation factor VII humanCoagulation factor IXtarget
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB00005EtanerceptProstaglandin G/H synthase 2enzyme
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogentarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinasePlasminogentarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseNidogen-1target
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogentarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00025Antihemophilic factor, human recombinantCoagulation factor Xtarget
DB00025Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB00025Antihemophilic factor, human recombinantCoagulation factor IXtarget
DB00025Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
DB00025Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
DB00025Antihemophilic factor, human recombinantCalreticulintarget
DB00025Antihemophilic factor, human recombinantCalnexintarget
DB00025Antihemophilic factor, human recombinantProtein ERGIC-53target
DB00025Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
DB00025Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
DB00025Antihemophilic factor, human recombinantvon Willebrand factortarget
DB00025Antihemophilic factor, human recombinantProthrombinenzyme
DB00025Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00028Immune Globulin HumanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00028Immune Globulin HumanHigh affinity immunoglobulin gamma Fc receptor IBtarget
DB00028Immune Globulin HumanComplement C3target
DB00028Immune Globulin HumanComplement C4-Atarget
DB00028Immune Globulin HumanComplement C4-Btarget
DB00028Immune Globulin HumanComplement C5target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogentarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factortarget
DB00036Coagulation factor VIIa Recombinant HumanSerine protease hepsintarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
DB00036Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB00051AdalimumabTumor necrosis factortarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00051AdalimumabComplement C1r subcomponenttarget
DB00051AdalimumabComplement C1q subcomponent subunit Atarget
DB00051AdalimumabComplement C1q subcomponent subunit Btarget
DB00051AdalimumabComplement C1q subcomponent subunit Ctarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00051AdalimumabComplement C1s subcomponenttarget
DB00051AdalimumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00057Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
DB00058Alpha-1-proteinase inhibitorNeutrophil elastasetarget
DB00062Human Serum AlbuminApolipoprotein Etarget
DB00062Human Serum AlbuminSerum amyloid A-1 proteintarget
DB00062Human Serum AlbuminProtein AMBPtarget
DB00062Human Serum AlbuminCytochrome P450 2C9enzyme
DB00062Human Serum AlbuminMyeloperoxidaseenzyme
DB00062Human Serum AlbuminUDP-glucuronosyltransferase 1-9enzyme
DB00065InfliximabTumor necrosis factortarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00072TrastuzumabCytochrome P450 19A1enzyme
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00073RituximabComplement C1r subcomponenttarget
DB00073RituximabComplement C1q subcomponent subunit Atarget
DB00073RituximabComplement C1q subcomponent subunit Btarget
DB00073RituximabComplement C1q subcomponent subunit Ctarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00073RituximabComplement C1s subcomponenttarget
DB00073RituximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00074BasiliximabInterleukin-2 receptor subunit alphatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00074BasiliximabComplement C1r subcomponenttarget
DB00074BasiliximabComplement C1q subcomponent subunit Atarget
DB00074BasiliximabComplement C1q subcomponent subunit Btarget
DB00074BasiliximabComplement C1q subcomponent subunit Ctarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00074BasiliximabComplement C1s subcomponenttarget
DB00074BasiliximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00074BasiliximabInterleukin-2 receptor subunit betatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00078Ibritumomab tiuxetanB-lymphocyte antigen CD20target
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00078Ibritumomab tiuxetanComplement C1r subcomponenttarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Atarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Btarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Ctarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00078Ibritumomab tiuxetanComplement C1s subcomponenttarget
DB00078Ibritumomab tiuxetanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00081TositumomabB-lymphocyte antigen CD20target
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00081TositumomabComplement C1r subcomponenttarget
DB00081TositumomabComplement C1q subcomponent subunit Atarget
DB00081TositumomabComplement C1q subcomponent subunit Btarget
DB00081TositumomabComplement C1q subcomponent subunit Ctarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00081TositumomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00086StreptokinasePlasminogentarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00089Capromab pendetideGlutamate carboxypeptidase 2target
DB00095EfalizumabIntegrin alpha-Ltarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00095EfalizumabComplement C1r subcomponenttarget
DB00095EfalizumabComplement C1q subcomponent subunit Atarget
DB00095EfalizumabComplement C1q subcomponent subunit Btarget
DB00095EfalizumabComplement C1q subcomponent subunit Ctarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00095EfalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
DB00098Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
DB00098Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
DB00098Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DB00102BecaplerminPlatelet-derived growth factor receptor betatarget
DB00102BecaplerminAlpha-2-macroglobulintarget
DB00102BecaplerminPlatelet-derived growth factor receptor alphatarget
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00110PalivizumabFusion glycoprotein F0target
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00110PalivizumabComplement C1r subcomponenttarget
DB00110PalivizumabComplement C1q subcomponent subunit Atarget
DB00110PalivizumabComplement C1q subcomponent subunit Btarget
DB00110PalivizumabComplement C1q subcomponent subunit Ctarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00110PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00113Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
DB01257EculizumabComplement C5target
DB01269PanitumumabEpidermal growth factor receptortarget
DB01270RanibizumabVascular endothelial growth factor Atarget
DB01277MecaserminInsulin-like growth factor 1 receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3target
DB01277MecaserminInsulin receptortarget
DB01277MecaserminCation-independent mannose-6-phosphate receptortarget
DB01281AbataceptT-lymphocyte activation antigen CD80target
DB01281AbataceptT-lymphocyte activation antigen CD86target
DB01373CalciumProtein S100-Btarget
DB01373CalciumCalpastatintarget
DB01373CalciumCartilage oligomeric matrix proteintarget
DB01373CalciumCalmodulintarget
DB01373CalciumSpectrin beta chain, non-erythrocytic 1target
DB01373CalciumVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01373CalciumTroponin C, skeletal muscletarget
DB01373CalciumTroponin C, slow skeletal and cardiac musclestarget
DB01373CalciumCalcium-transporting ATPase type 2C member 1target
DB01373CalciumAmiloride-sensitive amine oxidase [copper-containing]target
DB01373CalciumProtein S100-A13target
DB01373CalciumAlkaline phosphatase, placental typetarget
DB01373CalciumProtein S100-A8target
DB01373CalciumProtein S100-A9target
DB01373CalciumProtein S100-A2target
DB01373CalciumCeruloplasmintarget
DB01373CalciumBone morphogenetic protein 4target
DB01373CalciumMatrix Gla proteintarget
DB01373CalciumProtocadherin-19target
DB01373CalciumProgrammed cell death protein 6target
DB02261Platelet Activating FactorGanglioside GM2 activatortarget
DB02261Platelet Activating FactorMultidrug resistance protein 1transporter
DB02261Platelet Activating FactorPlatelet-activating factor receptortarget
DB04901GaliximabT-lymphocyte activation antigen CD80target
DB04925DesmoteplasePlasminogentarget
DB04956AfelimomabTumor necrosis factortarget
DB04958EpratuzumabB-cell receptor CD22target
DB04964OregovomabMucin-16target
DB04988IGN311Epidermal growth factor receptortarget
DB04988IGN311Receptor tyrosine-protein kinase erbB-2target
DB05097LabetuzumabCarcinoembryonic antigentarget
DB05101MatuzumabEpidermal growth factor receptortarget
DB05111FontolizumabInterferon gammatarget
DB05139CR002Platelet-derived growth factor Dtarget
DB05209SYM001Rhesus blood group D antigentarget
DB05276Hepatitis B Immune GlobulinHBsAgtarget
DB05299keyhole limpet hemocyaninInterleukin-2target
DB05459BriakinumabInterleukin-12 subunit betatarget
DB05459BriakinumabInterleukin-23 subunit alphatarget
DB05578RamucirumabVascular endothelial growth factor receptor 2target
DB05595FarletuzumabFolate receptor alphatarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineMultidrug resistance protein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB05793PRO-542Free fatty acid receptor 4target
DB05797TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
DB05889Inotuzumab ozogamicinMultidrug resistance protein 1transporter
DB05889Inotuzumab ozogamicinB-cell receptor CD22target
DB05892RI 624Beta-nerve growth factortarget
DB05915MYO-029Growth/differentiation factor 8target
DB06043OlaratumabPlatelet-derived growth factor receptor alphatarget
DB06101IMC-1C11Vascular endothelial growth factor receptor 1target
DB06101IMC-1C11Vascular endothelial growth factor receptor 2target
DB06101IMC-1C11Vascular endothelial growth factor receptor 3target
DB06168CanakinumabInterleukin-1 betatarget
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06317ElotuzumabSLAM family member 7target
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB06404Human C1-esterase inhibitorComplement C1r subcomponenttarget
DB06404Human C1-esterase inhibitorComplement C1s subcomponenttarget
DB06404Human C1-esterase inhibitorPlasma kallikreintarget
DB06404Human C1-esterase inhibitorCoagulation factor XIItarget
DB06404Human C1-esterase inhibitorProthrombintarget
DB06404Human C1-esterase inhibitorCoagulation factor XItarget
DB06404Human C1-esterase inhibitorTissue-type plasminogen activatortarget
DB06612MepolizumabInterleukin-5target
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB06650OfatumumabB-lymphocyte antigen CD20target
DB06674GolimumabTumor necrosis factortarget
DB06681BelataceptT-lymphocyte activation antigen CD86target
DB06681BelataceptT-lymphocyte activation antigen CD80target
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinCytochrome P450 3A5enzyme
DB08870Brentuximab vedotinMultidrug resistance protein 1transporter
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08902RaxibacumabProtective antigentarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09029SecukinumabInterleukin-17Atarget
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB09035NivolumabProgrammed cell death protein 1target
DB09036SiltuximabInterleukin-6target
DB09037PembrolizumabProgrammed cell death protein 1target
DB09045DulaglutideGlucagon-like peptide 1 receptortarget
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09077DinutuximabGanglioside GD2target
DB09105Asfotase AlfaSphingosine 1-phosphate receptor 1target
DB09105Asfotase AlfaPyrophosphatetarget
DB09264IdarucizumabDabigatran etexilatetarget
DB09302AlirocumabProprotein convertase subtilisin/kexin type 9target
DB09303EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DB09331DaratumumabADP-ribosyl cyclase 1target
DB09559NecitumumabEpidermal growth factor receptortarget